mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Please contact the Account Manager for opportunities with this organisation

Daiichi Sankyo product receives FDA approval for cholesterol-lowering drug

Posted on 12/11/2009 in Pharmaceutical Company Product News

Daiichi Sankyo has announced that its drug Welchol has been granted approval by the Food and Drug Administration (FDA) for use in heterozygous familial hypercholesterolemia patients attempting to lower their cholesterol levels.

The therapy has been approved as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol in boys and girls aged between the ages of ten and 17.

It can be taken alone or with a statin in those patients whose diet therapy has failed to prove effective.

Evan Stein, director of the Metabolic and Atherosclerosis Research Centre, stated: "The FDA approval of Welchol for children with inherited high cholesterol provides another important treatment option for these children, whose elevated LDL cholesterol puts them at increased risk of cardiovascular disease."

Last month, Daiichi Sankyo created a new subsidiary with Ranbaxy, which aims to produce products for the generic drugs market.

Other news stories from 12/11/2009

Read more in the Zenopa News Archive

How this news is generated

Alessia
Account Manager
for this opportunity

01494 818 010
(Mon to Fri 0830 to 1800 hours)
alessia@zenopa.com

Latest News

Daiichi Sankyo to proceed with phase III trial of cancer drug

Daiichi Sankyo enters new joint vaccine venture

Daiichi Sankyo publishes positive edoxaban trial data

Daiichi Sankyo proposes new president and CEO

Daiichi Sankyo reports positive Azor trial data

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use